March 1 (Reuters) - Exelixis Inc EXEL.O :
* Exelixis and Ipsen enter into exclusive licensing agreement
to commercialize and develop novel cancer therapy Cabozantinib in regions
outside the United States, Canada and Japan
* Says under the agreement, Exelixis will receive $200 million upfront payment
* Exelixis inc - co to maintain exclusive commercial rights for Cabozantinib in
U.S., Canada; continue discussions to partner commercial rights in Japan
* Says the agreement also includes up to $545 million of potential commercial
milestones for co
* Agreement also provides for Exelixis to receive tiered royalties up to 26% on
Ipsen's net sales of cabozantinib in its territories
* Source text for Eikon
* Further company coverage EXEL.O